Director RA Capital Management bought $6.9M of PBLS at $28.29, increasing its stake by 0.9% at a price 17.9% below the 90-day high. This reinforces a $10.7M cluster with Levy Guy ($10.0M) and Sebulsky ($724K), signaling continued insider confidence after a recent dip. Bull: holds above $25.56 → +9.4% base rate; bear breaks $24.51.

Where it could go — Our 7-8 conviction director buys: 66% beat SPY at 30d; bull holds $25.56, bear breaks $24.51.

10%+ beneficial owner Levy Guy built a $10M position (1847% stake increase) at $20.00, near the 90d low range. This first-ever buy coincides with a $424M cluster from RA Capital Management and another insider, representing significant institutional accumulation. Bull: Large unknown buyer entering alongside major fund → potential undisclosed catalyst or valuation play. Bear: No activist history limits upside; watch for follow-up filings.

Where it could go — First-time 10%+ owner accumulation at scale → 13D/13G may follow; bull confirmed above $26, bear breaks $20.

Director Alan Sebulsky bought $474K in PBLS shares at $27.06, increasing his stake by 140% in his second major purchase within a week. This repeated, high-conviction buying by a director suggests a strong belief in the company's value, though it lacks support from other officers.

Where it could go — Analyst mean target not available; broad universe of similar setups shows a 62.5% positive 90d rate.

RA Capital Management, a director, bought a $423.8M stake at $20.00 per share, establishing a new position at a price 24.8% above the 90-day low. This massive first-time investment by a major biotech-focused fund signals a high-conviction bet on the company's future, especially as it was made alongside a smaller $250K purchase by another insider. Bull: A successful hold above the $26.61 low could target a re-test of the $34.47 high, representing over 70% upside.

Where it could go — Broad base rate 62.5% positive at 90d; bull holds $26.61, bear breaks $20.00.

Director Alan Sebulsky bought $250,000 worth of PBLS stock, establishing a new position at a price 42% below the 90-day high. This first-ever buy by a long-tenured director near a low is a notable vote of confidence, though its significance is tempered by the absence of other insiders buying alongside him.

Where it could go — Analyst mean target not available; broad pattern data shows 62.5% of similar setups led to a higher stock price at 90 days.